Renuka
Sriram1, Robert J. Mather2, Serguei Liachenko1
1BioImaging CoE, Pfizer Inc, Groton,
CT, United States; 2Neuroscience, Pfizer Inc, Groton, CT, United
States
Neurotransmitter
levels of glutamate and glutamine are tightly coupled with modulation of one
resulting in a corresponding opposing change in the other. Since glutamate is
implicated in a variety of neurological disorders, the observation of an
endogenous pool of glutamate (Glu) and glutamine (Gln) and/or its ratio can
serve as a strong mechanistic biomarker and measure of efficacy. Flupirtine, a potassium channel opener, has
been shown to cause decrease in Glu and a relative increase in Gln in the rat
hippocampus.